C
ARDIAC SURGERY REMAINS the therapy of choice for advanced coronary artery disease or severe valve diseases. 1 Patients undergoing cardiac surgery are still at significantly higher risk for postoperative major adverse events. There has been great progress in surgical techniques and perioperative care over the past decades. Cardiac surgery has become individualized with regard to on-pump or off-pump procedures, minimally invasive procedures, robotic surgeries, and various myocardial protection strategies.
2,3 However, these significant developments are counteracted by the presence of increasing comorbidities in the aging patient population. Mortality rates have not decreased over the past decade; thus, it is imperative to explore better strategies to reduce the risk for major adverse events after cardiac surgery.
The renin-angiotensin system (RAS) plays important roles in atherosclerosis, hypertension, left ventricular hypertrophy, myocardial infarction (MI), and congestive heart failure (CHF). RAS inhibitors, including angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-receptor blockers (ARBs), have been shown to be effective in treating hypertension and decreasing cardiovascular mortality and morbidity. Commonly, they are used to treat hypertension, coronary artery disease, CHF, and diabetic nephropathy. [4] [5] [6] [7] It has been reported that long-term use of RAS inhibitors can provide end-organ protection and reduce cardiovascular and renal events in the patients with cardiovascular and kidney diseases. 8 However, the role of preoperative (pre-op) RAS inhibitors in patients undergoing cardiac surgery remains undefined, and the existing data from literature still are contradictory. Studies have found that pre-op ACEi reduced postoperative troponin release and protected renal functions in patients undergoing cardiac surgery. [9] [10] [11] But other studies have shown that pre-op ACEi/ARBs use either is associated with a higher risk (27.6%) for postoperative acute kidney injury (AKI) or has no effects on renal function at all after cardiovascular surgery. 12, 13 Thus, the aim of this study was to test the hypothesis that patients on RAS drugs would have worse outcomes due to the potential of renal injury.
2,322 met the inclusion criteria. All patients treated with ACEi/ARBs for at least 2 weeks constituted the RAS inhibitor group. They were compared with the remaining patients who had not received ongoing RAS inhibitor therapy (non-RAS inhibitor group) preoperatively.
Data were abstracted from a single institution's Society of Thoracic Surgeons (STS) database and hospital medical records, including demographics, pre-op risk factors, pre-op medications, intraoperative data, postoperative cardiocerebral events, renal function, and operative mortality. Independent investigators prospectively collected the data on each patient during the course of hospitalization.
The primary outcome was operative mortality, which is defined as any death occurring during the acute episode of care in which the surgery was performed, even after 30 days, and deaths occurring after discharge from the hospital, but within 30 days of the procedure unless the cause of death clearly is unrelated to the surgery. Secondary outcomes were AKI, perioperative MI, heart block, cardiac arrest, permanent stroke, and transient stroke. Other outcomes also included the following: readmission r30 days, deep sternum infection, septicemia, the postoperative length of hospital stay (LOS; d), the length of intensive care unit (ICU) stay (h), and the time on a ventilator (h).
Based on the STS database criteria, perioperative MI was defined by using the following criteria:
For an MI that occurred o24 hours postoperatively, CK-MB must be Z5 times the upper limit of normal, with or without new Qwaves present in 2 or more contiguous electrocardiogram (ECG) leads-no symptoms required.
An MI occurring 424 hours postoperatively by at least one of the following criteria: (1) evolutionary ST-segment elevations, (2) development of new Q-waves in 2 or more contiguous ECG leads, (3) new or presumably new left bundle-branch block pattern on the ECG, or (4) the CK-MB (or CK if MB not available) must be Z3 times the upper limit of normal value.
Heart block: defined as a new heart block requiring the implantation of a permanent pacemaker of any type before discharge. The remaining definitions are available at http://www.sts.org. AKI was defined using Acute Kidney Injury Network (AKIN) classification creatinine criteria 14 : Stage I, increase in serum creatinine by Z0.3 mg/dL or increase to Z150% to 200% from baseline (postoperative creatinine level divided by last creatinine level); stage II, increase in serum creatinine to 4200% to 300% from baseline; and stage III, increase in serum creatinine to 4300% from baseline or serum creatinine level Z4 mg/dL or treatment with new renal replacement therapy.
Bivariable analysis was performed between RAS inhibitors and each pre-op risk factor and surgery outcomes. The chi-square test was used for categoric variables, and the Student t-test was used for continuous variables. To mitigate selection bias in RAS inhibitor use, the authors computed the propensity score; that is, the conditional probability of each patient receiving RAS inhibitors with a multivariate logistic regression model that includes patient demographic and clinical risk factors. For real-time prediction of impact in using RAS inhibitor on surgery outcomes, 3 separate propensity-weighted multivariable logistic regression models were developed for operative mortality, postoperative AKI, and postoperative septicemia. Parsimonious models with a backward selection method from all candidate risk factors (a ¼ 0.05) were presented. The candidate risk factors were selected based on the literature reviews, clinical plausibilities, and variables collected in the database. These variables included RAS inhibitors, age, sex, race, procedure status, surgery type, body mass index, diabetes, hypertension, dyslipidemia, hypercholesterolemia, renal failure (RF), smoking, chronic lung disease, cerebrovascular disease, peripheral vascular disease, previous MI, CHF, ejection fraction (EF), intra-aortic balloon pump (IABP), CPB time, and aortic cross-clamp time. All differences in statistical analysis were considered significant if p o 0.05. All data analyses were conducted with SAS version 9.3 (Cary, NC).
RESULTS
Demographic and clinical data of those patients are presented in Table 1 . There were no significant differences in age, sex, body mass index, procedure status, smoking, peripheral vascular disease, last creatinine level, RF, CHF, pre-op inotropes, and preop b-blocker uses between the 2 groups. There were more Caucasian/white patients and more chronic lung diseases in the non-RAS inhibitors group. Patients who received pre-op RAS inhibitor therapy were more likely to have diabetes, hypertension, dyslipidemia, cerebrovascular disease, previous MI, lower EF, IABP, pre-op aspirin, lipid-lowering medications, and nitrates. Intraoperative characteristics, including CPB time and aortic cross-clamp time, were similar in both the groups (Table 1) .
Overall, the operative mortality was 3.7% (87/2,322). This study showed that the operative mortality was 2.99% (37/ 1,239) for patients who received pre-op RAS inhibitors and 4.62% (50/1,083) for patients who did not take pre-op RAS inhibitors (p ¼ 0.039, odds ratio [OR]: 0.636, 95% confidence interval [CI]: 0.42-0.981) (Fig. 1) . After excluding patients with pre-op RF, the total numbers of patients assessed for renal function outcome were 1,128 in the RAS inhibitor group and 985 in the non-RAS inhibitor group. There were significant differences between the RAS inhibitor group (27.2%) and the non-RAS inhibitor group (34.0%) in the incidence of AKI (p o 0.001, OR: 0.726, 95% CI: 0.602-0.874) (Fig. 1 ). There was a significant difference between the 2 groups in AKI stage I patients (23.1% v 28.2%, p ¼ 0.007). Although the results were in favor of the RAS inhibitor group, there were no statistical significances between the 2 groups in stage II and III groups. There was a significant difference between the RAS inhibitor group and non-RAS inhibitor group in the incidence of septicemia (1.9% v 3.5%, p ¼ 0.019, OR: 0.543, 95% CI: 0.324-0.912) (Fig. 1 ). There were no significant differences in perioperative MI, heart block, cardiac arrest, permanent stroke, transient stroke, deep sternum infection, and readmission r30 days between 2 groups (Fig. 1 ). There were also no significant differences in the length of ICU stay, the length on a ventilator, and the LOS between the 2 groups. Conditional logistic regression models were performed to identify risk factors for operative mortality, AKI, and septicemia.
Pre-op RAS inhibitor treatment was an independent protective factor for mortality (OR: 0.539, 95% CI: 0.384-0.758, p o 0.001). Other risk factors were advanced age, female gender, non-white race, RF, chronic lung disease, IABP, lower EF, and CPB time (Table 2) .
Pre-op RAS inhibitor treatment was an independent protective factor against AKI (OR: 0.764, 95% CI: 0.67-0.873, p o 0.001). Advanced age, diabetes, hypertension and chronic lung disease, valve surgery, and urgent surgery were risk factors of AKI (Table 3) .
Pre-op RAS inhibitor treatment was an independent protective factor against septicemia (OR: 0.515, 95% CI: 0.348-0.761, p o 0.001). Female, non-white race, RF, previous MI, CPB time, urgent surgery, and valve surgery were risk factors for septicemia (Table 4) .
The discriminatory ability of the multivariate logistic model was acceptable for operative mortality (C statistic: 0.819), AKI (C statistic: 0.651), and septicemia (C statistic: 0.827). The model was well calibrated among deciles of observed and expected risks for operative mortality (Hosmer-Lemeshow w 
DISCUSSION
The authors thought that patients on RAS inhibitors would do worse due to the potential cause of renal injury, but they actually did better. However, this study demonstrated that the pre-op RAS inhibitors reduced the incidence of postoperative AKI, septicemia, and operative mortality in patients undergoing cardiac surgery despite a sicker patient population. To the best of the authors' knowledge, this is the first study utilizing the AKIN classification to evaluate the renal outcome in patients who received RAS inhibitors under cardiac surgery and this study demonstrated that pre-op RAS inhibitors possess renal protective effect. Abbreviations: RAS, renin-angiotensin system; BMI, body mass index; CVD, cerebrovascular disease; PVD, peripheral vascular disease; MI, myocardial infarction; CHF, congestive heart failure; EF, ejection fraction; IABP, intra-aortic balloon pump; Pre-op, preoperative; CPB, cardiopulmonary bypass.
THE EFFECTS OF PREOPERATIVE RENIN-ANGIOTENSIN SYSTEM INHIBITORS
AKI or acute renal failure after cardiac surgery is now referred to collectively as cardiac surgery-associated AKI and associated with significantly poor outcomes including increased short-and long-term mortalities. 15 Operative mortality is 1% to 5% in patients who developed AKI and up to 24% in patients who required acute dialysis. 16 Its pathogenesis includes exogenous and endogenous toxins, metabolic factors, ischemia and reperfusion, neurohormonal activation, inflammation, and oxidative stress.
17
Angiotensin II increases the proliferation and migration of vascular smooth muscle cells and contributes to endothelial dysfunction, promoting the activity of nicotinamide adenine dinucleotide phosphate and xanthine oxidase, which are the main sources of oxygen free radicals. 18 Moreover, angiotensin II also can increase the expression of proinflammatory factors. 19 Studies have found that the patients receiving even shortterm (2 d) RAS inhibitors prior to CABG surgery had improved cardiac and renal functions following cardiac surgery. [20] [21] [22] [23] In a study of 536 patients, the pre-op ACEi was associated with a decreased incidence of postoperative AKI (OR: 0.48, 95% CI: 0.23-0.77, p ¼ 0.04) after on-pump CABG surgery.
11 Furthermore, pre-op RAS inhibitors also have shown renal protection in high-risk surgical populations. Age was one of the independent risk factors for postoperative AKI. 24 In a study of aged patients undergoing cardiac surgery, the incidence of postoperative the RF in the RAS inhibitor group was 1.6% v 7.6% in the non-RAS inhibitor group and an OR was 0.19 (95% CI: 0.04-0.84, p ¼ 0.029).
10 However, Ouzounian et al failed to find the benefits of RAS inhibitors in a similar clinical setting. 13 But there was a question in their patient population for assessing the RAS inhibitors on renal outcomes, the inclusion criteria should be patient without pre-op RF requiring dialysis, or pre-existing RF (defined by documented history of RF or creatinine level 42). If they had excluded the patients with pre-op RF, the incidence of new-onset RF would be 6.36% in patients with RAS inhibitors v 7.98% in patients without RAS inhibitors (p o 0.05) and RAS inhibitors would reduce the incidence of new-onset RF.
On the contrary, Miceli et al found that the ACEi was associated with an increased risk of postoperative renal dysfunction (PRD). There was a significant difference between Abbreviations: OR, odds ratio; CI, confidence interval; RAS, reninangiotensin system; EF, ejection fraction; CPB, cardiopulmonary bypass. the ACEi group and control group in the risk of PRD (7.1% v. 5.4%, OR: 1.36, 95% CI: 1.1-1.67, p ¼ 0.006). They defined PRD as a serum creatinine level 4200 mmol/L plus an increase of at least 1.5 times the preoperative baseline concentrations. 25 But there was a problem in their study that the pre-op renal function was unknown, so the results are questionable. Although these studies were assessing postoperative acute renal failure or AKI, they used different criteria or definitions, which likely led to different conclusions. It is very important to use a universal definition of AKI. This lack has resulted in substantial differences in the reported incidence and outcomes.
In the past decade, the renal injury definition/criteria has been evolved from the proposed AKI criteria in 2001 to the risk, injury, failure, loss of kidney function, and end-stage renal disease (RIFLE) classification in 2004 and the AKIN classification in 2007. AKIN classification proposed new diagnostic criteria, which is defined as an abrupt (within 48 h) reduction in kidney function signified by an absolute increase in serum creatinine of Z0.3 mg/dL (or 1.5 fold from the baseline), or a reduction in urine output to o0.5 mL/kg/h for 46 hours. 26 An earlier diagnosis would assist with treatment and avoid dehydration, excessive diuretic use, and other nephrotoxic intervention.
In this study, the authors chose to use AKIN classification instead of STS specifications. AKIN classification has a higher sensitivity and specificity, and it can describe the severity levels that predict the prognosis. There is accumulating evidence that small increments in serum creatinine are associated with adverse outcomes that are manifested in increased short-term morbidity/mortality and worsening of longer-term outcomes, including 1-year mortality. 27 This study demonstrated that the incidence of septicemia was decreased significantly in patients who received pre-op RAS inhibitors. Pre-op RAS inhibitors can reduce the incidence of septicemia by 46%. In a logistic regression model for postoperative septicemia, the pre-op RAS inhibitors use was an independent protective factor for septicemia. Sepsis and septicemia are 2 closely related medical conditions, both involving widespread inflammation and infection. There were limited reports about the effect of RAS inhibitors on septicemia in patients undergoing cardiac surgery. However, a study in laboratory animals exposed to endotoxin demonstrated that the RAS inhibition played an important role in decreasing oxidative stress and endothelial dysfunction.
28 RAS inhibitors could improve endothelium-dependent relaxation by decreasing endothelial-derived adhesion molecule production. These also have also been demonstrated to improve gut perfusion and reduce end-organ failure in critically ill patients. 29 Studies also have found that RAS inhibitors can prevent lipopolysaccharideinduced septic shock and block lipopolysaccharide-induced inflammatory response in animal models. The authors suggested that enalapril would be a good therapeutic agent for sepsis. 30 The reduction of septicemia in the RAS inhibitor group was likely to be associated with the reduction of AKI. Accumulating data indicated that AKI could trigger immune, metabolic, and hormonal response pathways. Septicemia and AKI are bidirectional. Sepsis is the most common precipitating factor for AKI in hospitalized patients, and, similarly, patients with AKI are predisposed to sepsis. AKI not only complicates the course of sepsis, but also appears to predispose patients to further development of sepsis. 31 This study showed that the pre-op RAS inhibitor therapy reduced the mortality by 35%. In a multivariate logistic regression model for operative mortality, age, sex, urgent surgery, RF, chronic lung diseases, IABP, and CPB time are all risk factors of operative mortality, and pre-op RAS inhibitor therapy has a protective effect on operative mortality. The mechanism of the reduction of operative mortality in patients who received RAS inhibitors was likely associated with the renal protective effect of RAS inhibitors. AKI and septicemia are statistically significant risk factors for operative mortality. The reductions of AKI and septicemia in the RAS inhibitor group may also have played a key role in decreasing operative mortality. Abbreviations: OR, odds ratio; CI, confidence interval; RAS, reninangiotensin system; CABG, coronary artery bypass graft; MI, myocardial infarction; CPB, cardiopulmonary bypass.
THE EFFECTS OF PREOPERATIVE RENIN-ANGIOTENSIN SYSTEM INHIBITORS
There is a debate about whether to stop or continue the RAS inhibitors prior to cardiac surgery. Some believe that RAS inhibitors are associated with intraoperative hypotension and low cardiac output after bypass and others may disagree. 32 In a prospective observational study, Drenger et al suggested that continuous treatment with ACEi was associated with substantive reductions of risk of nonfatal events. 33 In a review, Auron et al suggested that full discussion of the potential implications of perioperative RAS inhibitors therapy with the surgical team is important, and strategies to ensure careful monitoring and maintenance of adequate intravenous volume before induction of anesthesia are essential. 34 This study had several limitations. One challenge in conducting observational studies is to draw inferences that are acceptably free from influences by overt and/or potential hidden biases, including potential multiple and uncontrollable confounding factors, such as physician bias on selection of patients and medications. Although multivariate regression was used in this study to reduce overt biases, the potential flaws of a nonrandomized study may remain. A second limitation was that this study only focused on ACEi and there are other interventions, such as statins, that have significant benefits on outcomes after cardiac surgery. Same as sterois, it could potentially improve cardiac surgery outcomes. 35, 36 Thirdly, this was a single-center study with the data from a 10-year period. Nevertheless, further multicenter studies are needed.
This study demonstrated that pre-op RAS inhibitor use was an independent protective factor against AKI and septicemia. It can reduce the incidence of AKI, septicemia, and operative mortality and improve outcomes in patients undergoing cardiac surgery.
